Consumer Services · NSE: JSLL
Jeena Sikho Lifecare
Q2 FY27 earnings highlights, from the results presentation
Q2 FY27 · From the investor presentation
- M.Cap
- ₹3,859Cr
- P/E
- 18.0×
- 1Y return
- −56.24%
- From 52W high
- −61.6%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 235 | 190 | +23.9% | 224 | +4.8% |
| EBITDA | 72 | 92 | -21.8% | 92 | -21.8% |
| EBITDA margin | 30.6% | 48.5% | -1785 bps | 41.0% | -1041 bps |
| PBTProfit before tax | 50 | 79 | -37.1% | 88 | -43.4% |
| Net profit | 37 | 59 | -37.6% | 66 | -44.4% |
| EPS (₹) | 2.94 | 4.72 | -37.7% | 5.29 | -44.4% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
More figures from the presentation
“• Lucknow – 160 beds”
“• Bareilly – 40 beds”
“• Ahmedabad – 200 beds”
“• Kalyani, West Bengal – 60 beds”
“• 108 rooms, 22 villas and a helipad”
“Total CAPEX ₹250 - 350 lakhs”
In short
- 01H1 EBITDA was ₹164 crore at a 36% margin and PAT ₹102 crore; Q2 EBITDA margin was 31%.
- 02Higher advertising (₹13.4 crore), staff (₹4.1 crore) and ECL provision (₹2.5 crore) costs were cited.
- 03Company aims for about 5,000 beds in 2-5 years and 10,000 in 5-10 years, from 3,031 now.
- 04Network is 2,424 operational beds with 460 in pipeline, including four upcoming facilities.
- 05Growth is to be funded from internal accruals with a debt-free balance sheet.
- 06Company has signed its first wellness resort in Manali, entering premium wellness.
Capacity
Bed occupancy 57.0% in H1 FY27, same as H1 FY26
Slides · p. 13
Bed occupancy 57.0% in H1 FY27, same as H1 FY26
“No. of Operational beds Occupancy 57.0% 57.0%”
Segments
Ayurveda Healthcare Products: H1 products revenue ₹262 crore (57%) and services ₹197 crore (43%)
Slides · p. 8
Ayurveda Healthcare Products: H1 products revenue ₹262 crore (57%) and services ₹197 crore (43%)
“The business is now well balanced: Ayurveda Healthcare Products contributed ₹262 crore (57%) and Healthcare Services ₹197 crore (43%) in H1FY27, with gross margins”
Demand
H1 IPD volumes up 23% to 22,480; OPD volumes up 17% to 3.1 lakh
Slides · p. 8
H1 IPD volumes up 23% to 22,480; OPD volumes up 17% to 3.1 lakh
“IPD volumes grew 23% YoY to 22,480, OPD volumes grew 17% to 3.1 lakh,”
Health camps convert about 30% of attendees to IPD treatment on average
Slides · p. 52
Health camps convert about 30% of attendees to IPD treatment on average
“Average ~30% conversion of camp attendees for IPD”
Most key Indian states are below WHO norm of 3.0 beds per 1,000 people
Slides · p. 48
Most key Indian states are below WHO norm of 3.0 beds per 1,000 people
“Most key Indian states fall significantly short of the WHO recommendation of 3.0 beds per 1,000 population, with major deficit in markets like Odisha, Uttar Pradesh and Haryana offering long-term structural expansion runway.”
Group and individual share of insured lives rose from 35% in FY18 to 58% in FY25
Slides · p. 48
Group and individual share of insured lives rose from 35% in FY18 to 58% in FY25
“The combined share of Group + Individual policies in total lives covered surged from 35% in FY18 to 58%”
H1 FY27 day care volumes up 27%; virtual OPD consultations up 39% to 1.36 lakh
Slides · p. 8
H1 FY27 day care volumes up 27%; virtual OPD consultations up 39% to 1.36 lakh
“day care volumes grew 27%, and virtual OPD consultations grew 39% to 1.36”
Margins and costs
Growth was volume-led in both verticals; gross margin held at 88%
Slides · p. 8
Growth was volume-led in both verticals; gross margin held at 88%
“volume-led across both verticals, and gross margin held firm at 88%, underlining the pricing strength of our integrated model.”
H1 EBITDA ₹164 crore at 36% margin, PAT ₹102 crore; Q2 EBITDA margin 31%
Slides · p. 8
H1 EBITDA ₹164 crore at 36% margin, PAT ₹102 crore; Q2 EBITDA margin 31%
“With depreciation also rising on the larger network, EBITDA stood at ₹164 crore with a margin of 36%, and PAT at ₹102 crore. Q2FY27 EBITDA margin was 31%.”
Advertisement and promotion expenses up Rs 13.4 crore for brand building aimed at Gen Z
Slides · p. 39
Advertisement and promotion expenses up Rs 13.4 crore for brand building aimed at Gen Z
“Operating expense include Advertisement and promotion expenses increased by Rs. 13.4 crore driven by strategic brand building initiatives focused on expanding the company reach among younger consumer specifically Gen Z, including”
Employee expenses up Rs 4.1 crore from hiring ahead of expansion and salary revisions
Slides · p. 39
Employee expenses up Rs 4.1 crore from hiring ahead of expansion and salary revisions
“Operating expense also includes Employee benefit expenses increased by Rs 4.1 crore due to additional manpower, hiring new talent in markets ahead of planned expansion and performance-linked salary revisions.”
Management expects operating leverage to return after brand and capability investments
Slides · p. 8
Management expects operating leverage to return after brand and capability investments
“These are investments in brand and capability, and we expect operating leverage to”
Debt and working capital
Acquisitions and new business
premium wellness: First wellness resort signed in Manali, Himachal Pradesh
Slides · p. 34
premium wellness: First wellness resort signed in Manali, Himachal Pradesh
“First wellness resort signed in Manali, Himachal Pradesh”
Ayurveda Healthcare Products: Upcoming product launches: Dr. DS range, protein and joint-care
Slides · p. 35
Ayurveda Healthcare Products: Upcoming product launches: Dr. DS range, protein and joint-care
“• Dr. DS range, protein & joint-care launches”
Ayurveda Healthcare Products: Plans for own e-commerce platform and refill subscriptions
Slides · p. 35
Ayurveda Healthcare Products: Plans for own e-commerce platform and refill subscriptions
“• Own e-commerce platform & refill subscriptions”
Ayurveda Healthcare Products: Pharmacy and retail roll-out in pipeline
Slides · p. 35
Ayurveda Healthcare Products: Pharmacy and retail roll-out in pipeline
“• Pharmacy & retail roll-out in pipeline”
Dividends and buybacks
Company cites consistent and growing dividend payout
Slides · p. 23
Company cites consistent and growing dividend payout
“• Consistent & growing dividend payout in”
Management
Forvis Mazars appointed as new internal auditor
Slides · p. 23
Forvis Mazars appointed as new internal auditor
“• Forvis Mazars Appointed as the new Internal”
One-offs
Q2 FY27 other income was negative ₹231 lakh versus ₹1,402 lakh in Q1
Slides · p. 39
Q2 FY27 other income was negative ₹231 lakh versus ₹1,402 lakh in Q1
“OTHER INCOME (231) 1,402 (116%) 144 (260%)”
Risks
ECL provision up Rs 2.5 crore based on collection experience with government customers
Slides · p. 39
ECL provision up Rs 2.5 crore based on collection experience with government customers
“Operating expense also includes ECL provision increased by Rs. 2.5 crore, reflecting a prudent provisioning approach based on recent collection experience and settlement patterns from government customers.”
Other
Revenue from operations ₹460 crore in H1 FY27; Q2 FY27 ₹235 crore, up 24% YoY
Slides · p. 8
Revenue from operations ₹460 crore in H1 FY27; Q2 FY27 ₹235 crore, up 24% YoY
“YoY to ₹460 crore in H1FY27 and 24% YoY to ₹235 crore in Q2FY27.”
Q2 FY27 EBITDA ₹7,202 lakh, down 22% YoY and 22% QoQ
Slides · p. 39
Q2 FY27 EBITDA ₹7,202 lakh, down 22% YoY and 22% QoQ
“EBITDA 7,202 9,212 (22%) 9,206 (22%)”
Q2 FY27 PAT ₹3,634 lakh, down 45% QoQ and 38% YoY
Slides · p. 39
Q2 FY27 PAT ₹3,634 lakh, down 45% QoQ and 38% YoY
“PROFIT AFTER TAXES 3,634 6,569 (45%) 5,879 (38%)”
Priorities include entering premium wellness through first resort in Manali
Slides · p. 8
Priorities include entering premium wellness through first resort in Manali
“enter premium wellness through our first resort in Manali.”
52 NABH-accredited units, 12 more in process
Slides · p. 8
52 NABH-accredited units, 12 more in process
“With 52 NABH-accredited units and 12 in process, quality remains central to”
Sources
- Investor presentation, Q2 FY27 Filed 15 Nov 2026 · 58 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

